GlassScriptPhysician profile
Matthew M Morgan
NPI 1457322943
$19,180.54
in general payments reported to CMS, 2019-2025
60 companies · $3,099 in 2025
The $3,099 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,186 · 2020: $2,141 · 2021: $2,936 · 2022: $2,776 · 2023: $3,256 · 2024: $2,786 · 2025: $3,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,141.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,044.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,796.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,391.26 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,187.61 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $1,171.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $968.32 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $948.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $743.92 | 2019-2025 | Spravato, Xarelto |
| Pfizer INC. | $724.31 | 2019-2025 | |
| Abbott Laboratories | $473.84 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $465.89 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.88 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $416.22 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $339.72 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $334.35 | 2019-2024 | Austedo Xr, Austedo |
Show all 58 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.